Evaxion Biotech A/S (EVAX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 3 | 8 | 7 | 16 |
| Operating profit | $m | -9 | -9 | ||||||
| Net profit | $m | -15 | -25 | -23 | -22 | -11 | -8 | -9 | - |
| EPS reported | $ | -1.21 | -6.20 | ||||||
| Operating cashflow per share | $ | -1.04 | 0.00 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -1.04 | 0.00 | ||||||
| Free cash flow | $m | -7 | 0 | ||||||
| Net debt | $m | -18 | -7 | ||||||
| Book value equity | $m | 17 | 10 | ||||||
| Book value per share | $ | 2.66 | 22.86 | ||||||
| Number of shares | m | 6.41 | 0.42 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 1.79 | 3.21 | ||||||
| P/S LTM | x | 4.06 | 4.08 | ||||||
| P/FCF LTM | x | -4.59 | 0.00 | ||||||
| EV/EBITDA LTM | x | -2.08 | -1.49 | ||||||
| EV/Sales LTM | x | 1.97 | 0.35 | ||||||
| Earnings Yield LTM | % | -25.21% | -35.04% | ||||||
| FCF Yield | % | -21.78% | 0.00% | ||||||
| Quality | |||||||||
| ROE | % | -45.23% | -73.56% | ||||||
| ROIC | % | -33.44% | -35.48% | ||||||
| Operating margin | % | -1.23% | -1.22% | ||||||
| Gross margin | % | +100.00% | +100.00% | ||||||
| FCF/Sales | % | -88.42% | 0.00% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +125.12% | +124.04% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.89 | 0.00 | ||||||
| Net Debt/EBITDA | x | 2.21 | 1.70 | ||||||
| EBIT/Net interest | x | -10.54 | -11.33 | ||||||
| Net debt/market cap | % | +18.11% | 0.00% | ||||||
| Net debt/Equity | x | -1.04 | -0.72 | ||||||
| Gross debt/equity | x | 0.44 | 0.75 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free